[OPERa Study].
Identifieur interne : 000520 ( Main/Exploration ); précédent : 000519; suivant : 000521[OPERa Study].
Auteurs : P. Tesa OváSource :
- Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti [ 0862-495X ] ; 2013.
English descriptors
- KwdEn :
- Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Female, Fever (chemically induced), Fever (epidemiology), Fever (prevention & control), Granulocyte Colony-Stimulating Factor (therapeutic use), Humans, Incidence, Length of Stay, Male, Neoplasms (drug therapy), Neoplasms (immunology), Neutropenia (chemically induced), Neutropenia (epidemiology), Neutropenia (prevention & control), Practice Guidelines as Topic, Recombinant Proteins (therapeutic use), Risk Factors.
- MESH :
- chemical , therapeutic use : Granulocyte Colony-Stimulating Factor, Recombinant Proteins.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemically induced : Fever, Neutropenia.
- drug therapy : Neoplasms.
- epidemiology : Fever, Neutropenia.
- immunology : Neoplasms.
- prevention & control : Fever, Neutropenia.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Age Factors, Aged, Female, Humans, Incidence, Length of Stay, Male, Practice Guidelines as Topic, Risk Factors.
Abstract
On the whole, most European and international guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSFs) when the risk of chemotherapy-induced febrile neutropenia (FN) in cancer patients exceeds 20%. In patients treated with intermediate-risk chemotherapy regimens the recent EORTC guidelines recommend to consider supplementary patient-related adverse risk factors such as elderly age ( 65 years) prior to administrating each cycle of chemotherapy. The primary objective of our study is to describe the most important FN risk factors that underlie the use of pegfilgrastim PP in daily practice in the Czech Republic; secon-dary endpoints include FN incidence, chemotherapy dose intensity, anti-infective agents admini-stration, hospitalization length and safety of chemotherapy regimens.
PubMed: 24320592
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000192
- to stream PubMed, to step Curation: 000192
- to stream PubMed, to step Checkpoint: 000195
- to stream Ncbi, to step Merge: 000B46
- to stream Ncbi, to step Curation: 000B46
- to stream Ncbi, to step Checkpoint: 000B46
- to stream Main, to step Merge: 000513
- to stream Main, to step Curation: 000520
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[OPERa Study].</title><author><name sortKey="Tesa Ova, P" sort="Tesa Ova, P" uniqKey="Tesa Ova P" first="P" last="Tesa Ová">P. Tesa Ová</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24320592</idno><idno type="pmid">24320592</idno><idno type="wicri:Area/PubMed/Corpus">000192</idno><idno type="wicri:Area/PubMed/Curation">000192</idno><idno type="wicri:Area/PubMed/Checkpoint">000195</idno><idno type="wicri:Area/Ncbi/Merge">000B46</idno><idno type="wicri:Area/Ncbi/Curation">000B46</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B46</idno><idno type="wicri:Area/Main/Merge">000513</idno><idno type="wicri:Area/Main/Curation">000520</idno><idno type="wicri:Area/Main/Exploration">000520</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[OPERa Study].</title><author><name sortKey="Tesa Ova, P" sort="Tesa Ova, P" uniqKey="Tesa Ova P" first="P" last="Tesa Ová">P. Tesa Ová</name></author></analytic><series><title level="j">Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti</title><idno type="ISSN">0862-495X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Female</term><term>Fever (chemically induced)</term><term>Fever (epidemiology)</term><term>Fever (prevention & control)</term><term>Granulocyte Colony-Stimulating Factor (therapeutic use)</term><term>Humans</term><term>Incidence</term><term>Length of Stay</term><term>Male</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (immunology)</term><term>Neutropenia (chemically induced)</term><term>Neutropenia (epidemiology)</term><term>Neutropenia (prevention & control)</term><term>Practice Guidelines as Topic</term><term>Recombinant Proteins (therapeutic use)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fever</term><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Fever</term><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Fever</term><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Length of Stay</term><term>Male</term><term>Practice Guidelines as Topic</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">On the whole, most European and international guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSFs) when the risk of chemotherapy-induced febrile neutropenia (FN) in cancer patients exceeds 20%. In patients treated with intermediate-risk chemotherapy regimens the recent EORTC guidelines recommend to consider supplementary patient-related adverse risk factors such as elderly age ( 65 years) prior to administrating each cycle of chemotherapy. The primary objective of our study is to describe the most important FN risk factors that underlie the use of pegfilgrastim PP in daily practice in the Czech Republic; secon-dary endpoints include FN incidence, chemotherapy dose intensity, anti-infective agents admini-stration, hospitalization length and safety of chemotherapy regimens.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Tesa Ova, P" sort="Tesa Ova, P" uniqKey="Tesa Ova P" first="P" last="Tesa Ová">P. Tesa Ová</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24320592
|texte= [OPERa Study].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24320592" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |